Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Articles published by Design Therapeutics, Inc.

Design Therapeutics to Participate in the 2024 Cantor Global Healthcare Conference
From Design Therapeutics, Inc.
Via GlobeNewswire
Tickers DSGN
Design Therapeutics Announces Second Quarter 2024 Financial Results and Reviews Near-term Milestones for GeneTAC™ Portfolio
From Design Therapeutics, Inc.
Via GlobeNewswire
Tickers DSGN
Design Therapeutics Announces First Quarter 2024 Financial Results and Highlights Upcoming Program Milestones
From Design Therapeutics, Inc.
Via GlobeNewswire
Tickers DSGN
Design Therapeutics to Participate in the 2024 RBC Capital Markets Global Healthcare Conference
From Design Therapeutics, Inc.
Via GlobeNewswire
Tickers DSGN
Design Therapeutics Outlines Progress Across GeneTAC™ Platform and Announces Fourth Quarter and Full Year 2023 Financial Results
From Design Therapeutics, Inc.
Via GlobeNewswire
Tickers DSGN
Design Therapeutics to Webcast Fourth Quarter and Full Year 2023 Financial Results and Comprehensive Portfolio Update
From Design Therapeutics, Inc.
Via GlobeNewswire
Tickers DSGN
Design Therapeutics Reports Third Quarter 2023 Financial Results and Plans for a Comprehensive Portfolio Update in Early 2024
From Design Therapeutics, Inc.
Via GlobeNewswire
Tickers DSGN
Design Therapeutics Provides Pipeline Update and Reports Second Quarter 2023 Financial Results
From Design Therapeutics, Inc.
Via GlobeNewswire
Tickers DSGN
Design Therapeutics Reports Initial Results from Phase 1 Multiple-Ascending Dose Study of DT-216 for the Treatment of Friedrich Ataxia
From Design Therapeutics, Inc.
Via GlobeNewswire
Tickers DSGN
Design Therapeutics to Present at the 2023 Jefferies Healthcare Conference
From Design Therapeutics, Inc.
Via GlobeNewswire
Tickers DSGN
Design Therapeutics Provides Pipeline Updates and Reports First Quarter 2023 Financial Results
From Design Therapeutics, Inc.
Via GlobeNewswire
Tickers DSGN
Design Therapeutics to Present Preclinical Data on its GeneTAC™ Small Molecule, DT-168, for the Treatment of Fuchs Endothelial Corneal Dystrophy at ARVO 2023
From Design Therapeutics, Inc.
Via GlobeNewswire
Tickers DSGN
Design Therapeutics Highlights Pipeline Progress and Reports Fourth Quarter and Full Year 2022 Financial Results
From Design Therapeutics, Inc.
Via GlobeNewswire
Tickers DSGN
Design Therapeutics to Participate in the SVB Securities Virtual Global Biopharma Conference
From Design Therapeutics, Inc.
Via GlobeNewswire
Tickers DSGN
Design Therapeutics Reports Positive Data from Single-Ascending Dose Trial of DT-216 for the Treatment of Friedreich Ataxia and Portfolio Progress
From Design Therapeutics, Inc.
Via GlobeNewswire
Tickers DSGN
Design Therapeutics Highlights Pipeline Progress and Upcoming Milestones and Reports Third Quarter 2022 Financial Results
From Design Therapeutics, Inc.
Via GlobeNewswire
Tickers DSGN
Design Therapeutics to Present Preclinical Data Highlighting the Potential of its GeneTAC™ Small Molecule, DT-216, for the Treatment of Friedreich Ataxia at ICAR 2022
From Design Therapeutics, Inc.
Via GlobeNewswire
Tickers DSGN
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.